Literature DB >> 29408338

A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon.

Paul Curtiss1, Zachary Schwager1, Gabriela Cobos1, Kristen Lo Sicco1, Andrew G Franks2.   

Abstract

BACKGROUND: Multiple placebo-controlled trials have assessed locally applied topical nitrate preparations in treating Raynaud's phenomenon (RP).
OBJECTIVES: The objective of this meta-analysis was to assess the effects of local topical nitrates in primary and secondary RP with respect to a combined end point integrating parameters of digital blood flow and clinical severity.
METHODS: A systematic review was performed using MEDLINE, Embase, and the Cochrane library. Only trials comparing locally applied topical nitrates with placebo comparators were included. Studies were appraised for bias by 2 independent reviewers.
RESULTS: A total of 7 placebo-controlled trials including 346 patients were used in the meta-analysis; 4 trials used nitroglycerin ointments, 2 used the nitroglycerin gel vehicle MQX-503, and 1 used compounded nitrite. The meta-analysis results supported a moderate-to-large treatment effect in RP (standardized mean difference [SMD] = 0.70; 95% CI, 0.35-1.05; P < .0001). Subgroup analyses showed a large treatment effect in secondary RP (SMD = 0.95; 95% CI, 0.25-1.65; P = .008) and moderate effect in primary RP (SMD = 0.45; 95% CI, 0.05-0.85; P = .03). LIMITATIONS: Limitations include the inclusion of multiple topical nitrate preparations and integration of different outcomes assessments.
CONCLUSION: Local topical nitrates have significant efficacy in the treatment of both primary and secondary RP.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Raynaud's phenomenon; connective tissue disease; medical dermatology; meta-analysis; scleroderma

Mesh:

Substances:

Year:  2018        PMID: 29408338     DOI: 10.1016/j.jaad.2018.01.043

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review.

Authors:  Olivia Qiu; Theresa Chan; Matthew Luen; Joseph E Cruz; Evelyn R Hermes-DeSantis
Journal:  Rheumatol Int       Date:  2018-08-22       Impact factor: 2.631

Review 2.  Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2019-02-13

Review 3.  Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

Authors:  Andreu Fernández-Codina; Esperanza Cañas-Ruano; Janet E Pope
Journal:  J Scleroderma Relat Disord       Date:  2019-01-28

Review 4.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

5.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

6.  Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Authors:  Alicia M Hinze; Fredrick M Wigley
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-07-04

Review 7.  Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.

Authors:  Djúlio César Zanin-Silva; Maynara Santana-Gonçalves; Marianna Yumi Kawashima-Vasconcelos; Maria Carolina Oliveira
Journal:  Front Med (Lausanne)       Date:  2021-12-22

Review 8.  Raynaud's Phenomenon with Focus on Systemic Sclerosis.

Authors:  Magdalena Maciejewska; Mariusz Sikora; Cezary Maciejewski; Rosanna Alda-Malicka; Joanna Czuwara; Lidia Rudnicka
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.241

Review 9.  An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.

Authors:  Zsuzsanna H McMahan; Elizabeth R Volkmann
Journal:  Expert Opin Pharmacother       Date:  2020-07-17       Impact factor: 3.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.